SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(D'Amico AV)
 

Sökning: WFRF:(D'Amico AV) > Guideline for the m...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003755naa a2200469 4500
001oai:gup.ub.gu.se/43804
003SwePub
008240528s2007 | |||||||||||000 ||eng|
0247 a https://gup.ub.gu.se/publication/438042 URI
0247 a https://doi.org/10.1016/j.juro.2007.03.0032 DOI
040 a (SwePub)gu
041 a eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Thompson, I4 aut
2451 0a Guideline for the management of clinically localized prostate cancer: 2007 update.
264 1b Ovid Technologies (Wolters Kluwer Health),c 2007
520 a Purpose Previous studies demonstrated a negative correlation between prostate volume and biopsy yield. By decreasing prostate volume 5α-reductase inhibitors may enhance cancer detection, which may explain the greater detection of high grade tumors in the finasteride arm of the Prostate Cancer Prevention Trial. Materials and Methods A mathematical model was constructed to analyze the effects of prostate and tumor volumes, and biopsy core number on cancer detection. The effects of the volume reduction observed with finasteride in the Prostate Cancer Prevention Trial were also modeled, as was the potential reduction in tumor volume needed to explain the observed difference in prostate cancer detection. The model was also applied to the Reduction by Dutasteride of Prostate Cancer Events study. Results A higher number of biopsies are required to ensure a detection probability of 0.90 or greater in larger glands or with smaller tumors. In the Prostate Cancer Prevention Trial for a tumor volume of 1 cc a 17% increase in the detection rate in the finasteride arm would be predicted if there was no change in tumor volume, likewise the rate would be 11% to 17% for the dutasteride arm of the Reduction by Dutasteride of Prostate Cancer Events study. The calculated reduction in tumor volume needed to explain the difference in cancer detection between the finasteride and placebo arms of the Prostate Cancer Prevention Trial would be 51% to 66%. Conclusions This model provides guidance on the optimal number of biopsy cores that accord with an earlier model. These findings also suggest that, if there were no reduction in tumor volume, 5α-reductase inhibitor therapy could lead to excess cancer detection, including high grade tumors.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Urologi och njurmedicin0 (SwePub)302142 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Urology and Nephrology0 (SwePub)302142 hsv//eng
653 a prostate; prostatic neoplasms; biopsy; decision support techniques; androgens
7001 a Thrasher, JB4 aut
7001 a Aus, Gunnar,d 1958u Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences4 aut
7001 a Burnett, AL4 aut
7001 a Canby-Hagino, ED4 aut
7001 a Cookson, MS4 aut
7001 a D'Amico, AV4 aut
7001 a Dmochowski, RR4 aut
7001 a Eton, DT4 aut
7001 a Forman, JD4 aut
7001 a Goldenberg, SL4 aut
7001 a Hernandez, J4 aut
7001 a Higano, CS4 aut
7001 a Kraus, SR4 aut
7001 a Moul, JW4 aut
7001 a Tangen, CM4 aut
7102 a Göteborgs universitetb Institutionen för kliniska vetenskaper4 org
7730 t J Urold : Ovid Technologies (Wolters Kluwer Health)g 177:6, s. 2106-2131q 177:6<2106-2131
7730 t Journal of Urologyd : Ovid Technologies (Wolters Kluwer Health)g 177:6, s. 2106-2131q 177:6<2106-2131x 0022-5347x 1527-3792
8564 8u https://gup.ub.gu.se/publication/43804
8564 8u https://doi.org/10.1016/j.juro.2007.03.003

Hitta via bibliotek

  • J Urol (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy